RNTX Rein Therapeutics Inc.

Price (delayed)

$0.7703

Market cap

$66.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.72

Enterprise value

$57.91M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 6

Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, ...

Highlights
The debt has dropped by 100% since the previous quarter
The EPS is up by 43% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of RNTX

RNTX stock price

How has the Rein Therapeutics stock price performed over time
Intraday
-3.07%
1 week
9.71%
1 month
-5.83%
1 year
-31.22%
YTD
-33.59%
QTD
-25.93%

Financial performance

How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.46M
Net income
-$49.76M
Gross margin
N/A
Net margin
N/A
The operating income has increased by 19% year-on-year
Rein Therapeutics's net income has increased by 16% YoY

Price vs fundamentals

How does RNTX's price correlate with its fundamentals

Growth

What is Rein Therapeutics's growth rate over time

Valuation

What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
1.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 43% year-on-year and by 9% since the previous quarter
RNTX's P/B is 32% below its last 4 quarters average of 1.8 but 23% above its 5-year quarterly average of 1.0
Rein Therapeutics's equity has increased by 15% YoY

Efficiency

How efficient is Rein Therapeutics business performance
The ROE has plunged by 60% YoY but it has grown by 6% from the previous quarter
The ROA has contracted by 39% YoY but it has grown by 6% from the previous quarter

Dividends

What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNTX.

Financial health

How did Rein Therapeutics financials performed over time
The company's total assets has surged by 151% QoQ and by 15% YoY
The total liabilities has decreased by 27% from the previous quarter but it has increased by 14% YoY
The debt is 100% smaller than the equity
RNTX's debt to equity has shrunk by 100% QoQ
The debt has dropped by 100% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.